Vistagen Therapeutics, Inc.
VTGN· Nasdaq
VTGNVistagen Therapeutics, Inc.
Filed Jun 11, 2024 · 10-K · 72 days after period end · 0001411685-24-000022
derived · Computed from the longer spans the company filed.
| Metric | Q4 2024dderived from reported figures | Q4 2023 | Q4 2022 | Q4 2021 |
|---|---|---|---|---|
| Revenue | $198.00K | $176.00K | $39.00K | $442.00K |
| Net Income | -$9.52M | -$12.23M | -$16.69M | -$6.21M |
| EPS Diluted | — | — | — | -$0.20 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vistagen Therapeutics, Inc. · CIK 1411685 · Engraved from SEC EDGAR
ended Mar 31, 2024 · filed Jun 11, 2024 · 72 d after period end
